Condition: Dedifferentiated Liposarcoma · Sponsor: Lund University Hospital
Dedifferentiated liposarcomas (DDLPS) are aggressive soft tissue sarcomas with no effective medical treatment options. Immunotherapy with checkpoint inhibitors, so-called PD-1 inhibitors, have shown some effect in DDLPS in previous studies. Effect of immunotherapy can be improved by combining it with other types of tumor drugs. Medicines that inhibit signaling via the FGF receptor, so-called FGFR inhibitors, have shown a tumor-slowing effect in DDLPS in early studies. FGFR inhibitors can also induce changes that make the tumor more available to treatment with immunotherapy. The study aims to investigate whether the combination of an FGFR inhibitor, pemigatinib, with a PD-1 inhibitor, retifanlimab can provide a tumor-slowing effect in patients with advanced DDLPS who have progressed on first-line treatment.
This description comes directly from the study's public registry record.
Helena Nyström, MD · +46 46 17 75 20 · helena.nystrom@skane.se
Liliya Shcherbina, PhD · liliya.shcherbina@skane.se
Always discuss trial participation with your own doctor first.
| Oslo University Hospital HF | Oslo, Norway | Recruiting |
| Sahlgrenska University Hospital | Gothenburg, Sweden | Recruiting |
| Skåne University Hospital | Lund, Sweden | Recruiting |
| Karolinska Universitetssjukhuset | Stockholm, Sweden | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06389799